Episode Details
Back to EpisodesSiri Needs an App, Apple Preps for Post-Cook, Scott Nolan Truth Nuke | Shervin Pishevar, Horacio Rozanski, Glenn Fogel, JD Ross, Nick Fleisher, Rob Slaughter, Sajith Wickramasekara
Episode 338
Published 22 hours ago
Description
Sign up for TBPN’s daily newsletter at TBPN.com
- (01:31) - John's Op-Ed: Siri Needs An App
- (23:51) - Apple Prepares For Post-Cook Era
- (37:31) - OpenAI Acquires Healthcare Startup Torch
- (41:34) - 𝕏 Timeline Reactions to Claude Cowork
- (01:00:30) - Shervin Pishevar is an Iranian-American entrepreneur and venture capitalist, known for co-founding Hyperloop One and Sherpa Capital, and for early investments in companies like Uber and Airbnb. In the conversation, Pishevar discusses the courage of millions of Iranians protesting for freedom, the oppressive actions of the regime, and the role of technologies like Starlink in supporting the movement. He emphasizes the need for international support, particularly from the U.S., to aid in the transition towards a democratic Iran.
- (01:20:54) - 𝕏 Timeline Reactions
- (01:31:07) - Horacio Rozanski, born in Argentina, is the Chairman, CEO, and President of Booz Allen Hamilton, a leading advanced technology company. In the conversation, he discusses his journey from an intern in 1991 to CEO in 2015, emphasizing the importance of aligning personal values with organizational culture. He also highlights Booz Allen's strategic focus on integrating advanced technologies like AI and cybersecurity into government missions, underscoring the firm's commitment to innovation and national security.
- (01:51:35) - Glenn Fogel, CEO of Booking Holdings and Booking.com, discusses the company's strategic initiatives, including the integration of agentic commerce and AI to enhance customer experiences. He emphasizes the importance of leveraging technology to streamline complex travel arrangements and improve customer service. Fogel also highlights the company's commitment to innovation and adaptability in the rapidly evolving travel industry.
- (02:14:17) - JD Ross is the co-founder of a company modernizing insurance brokerage by replacing traditional brokers with a platform for risk management. In the conversation, he discusses their recent $42 million Series B funding led by Keith Rabois and Sequoia, their flat-fee model aligning incentives with clients, and the integration of AI to enhance operational efficiency.
- (02:30:36) - Nick Fleisher, co-founder and CEO of Sandstone AI, discusses the company's recent $10 million seed funding led by Sequoia Capital and their mission to enhance in-house legal teams' efficiency through AI-driven solutions. He highlights the challenges legal teams face with scattered information and the need for a centralized platform that integrates various business systems to provide comprehensive context for legal workflows. Fleisher emphasizes that by automating routine tasks and consolidating data, Sandstone AI enables legal professionals to focus on strategic business discussions and proactive risk management.
- (02:39:48) - Rob Slaughter, a U.S. Air Force veteran with 13 years of active duty, co-founded Defense Unicorns to address significant technological challenges in the defense sector. He highlights the difficulties in delivering modern software to military systems due to air-gapped environments, stringent cybersecurity standards, and a skills gap among operators. Slaughter emphasizes the importance of enabling rapid software updates in mission-critical systems to maintain a strategic advantage.
- (02:48:51) - Sajith Wickramasekara, co-founder and CEO of Benchling, discusses how his company has spent a decade transitioning scientific research to the cloud and is now integrating AI into scientists' workflows to streamline drug discovery. He highlights the challenges in biotech, emphasizing the lengthy and complex process of bringing new medicines to market, and notes that while AI adoption in life sciences is growing, it requires significant effort to integrate effectively into existing systems. Wickramasekara also comments on the biotech industry's